Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Review of the safety of second-generation antipsychotics: are they really "atypically" safe for youth and adults?

Briles JJ, Rosenberg DR, Brooks BA, Roberts MW, Diwadkar VA.

Prim Care Companion CNS Disord. 2012;14(3). pii: PCC.11r01298. doi: 10.4088/PCC.11r01298.

2.

Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

Maher AR, Theodore G.

J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. Review.

PMID:
22784311
3.
4.

Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.

Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C.

J Clin Psychopharmacol. 2012 Jun;32(3):309-16. doi: 10.1097/JCP.0b013e3182549259. Review.

PMID:
22544019
5.
6.

Off-label second generation antipsychotics for impulse regulation disorders: a review.

Scheltema Beduin A, de Haan L.

Psychopharmacol Bull. 2010;43(3):45-81. Review.

PMID:
21150846
7.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients..

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

8.

The expert consensus guideline series. Treatment of behavioral emergencies 2005.

Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP; Expert Consensus Panel for Behavioral Emergencies 2005..

J Psychiatr Pract. 2005 Nov;11 Suppl 1:5-108; quiz 110-2.

PMID:
16319571
9.

Antipsychotics in pediatric and adolescent patients: a review of comparative safety data.

Ben Amor L.

J Affect Disord. 2012;138 Suppl:S22-30. doi: 10.1016/j.jad.2012.02.030. Review.

PMID:
22405602
10.

Second-generation antipsychotic medications in children and adolescents.

Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT.

J Child Adolesc Psychopharmacol. 2004 Fall;14(3):372-94. Review.

PMID:
15650494
11.

Atypicality of atypical antipsychotics.

Farah A.

Prim Care Companion J Clin Psychiatry. 2005;7(6):268-74.

12.

Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations.

Teixeira EH, Jacintho A, Celeri HV, Dalgalarrondo P.

Trends Psychiatry Psychother. 2013;35(3):151-9.

13.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. French.

PMID:
20620267
14.
15.

Selection of atypical antipsychotics for the management of schizophrenia.

Sprague DA, Loewen PS, Raymond CB.

Ann Pharmacother. 2004 Feb;38(2):313-9. Review.

PMID:
14742771
16.

Tolerability of atypical antipsychotics.

Stanniland C, Taylor D.

Drug Saf. 2000 Mar;22(3):195-214. Review.

PMID:
10738844
17.

Tolerability profile of atypical antipsychotics in children and adolescents.

Stigler KA, Potenza MN, McDougle CJ.

Paediatr Drugs. 2001;3(12):927-42. Review.

PMID:
11772153
18.

Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.

Maayan L, Correll CU.

J Child Adolesc Psychopharmacol. 2011 Dec;21(6):517-35. doi: 10.1089/cap.2011.0015. Review.

PMID:
22166172
19.

Overdoses and ingestions of second-generation antipsychotics in children and adolescents.

Antia SX, Sholevar EH, Baron DA.

J Child Adolesc Psychopharmacol. 2005 Dec;15(6):970-85.

PMID:
16379518
20.

Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review.

Gao K, Muzina D, Gajwani P, Calabrese JR.

J Clin Psychiatry. 2006 Sep;67(9):1327-40. Review.

PMID:
17017818
Items per page

Supplemental Content

Support Center